Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HVIVO plc
  6. News
  7. Summary
    VENN   GB00B9275X97

HVIVO PLC

(VENN)
  Report
Delayed London Stock Exchange  -  12:35:00 2023-03-24 pm EDT
14.95 GBX   -2.92%
03/16Inspirit Energy reports progress on Inspirit Charger
AN
03/16Inspirit Energy reports progress on Inspirit Charger
AN
02/06HVIVO signs GBP6.8 million deal to test RSV antiviral drug candidate
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

British COVID trial deliberately infecting young adults found to be safe

02/02/2022 | 10:30am EDT
FILE PHOTO: A 3D-printed coronavirus model is seen in front of the words coronavirus disease (Covid-19) on display in this illustration

LONDON (Reuters) -The world's first "human challenge" trial in which volunteers were deliberately exposed to COVID-19 to advance research into the disease was found to be safe in healthy young adults, leaders of the study said on Wednesday.

The data supports the safety of this model and lays the groundwork for future studies to test new vaccines and medicines against COVID-19 using this kind of trial by the end of this year, the team added.

Open Orphan is running the project, launched last February, with Imperial College London, Britain's vaccines task force and Orphan's clinical company  hVIVO.

Scientists have used human challenge trials for decades to learn more about diseases such as malaria, flu, typhoid and cholera, and to develop treatments and vaccines against them.

The Imperial trial exposed 36 healthy male and female volunteers aged 18-29 years to the original SARS-CoV-2 strain of the virus and monitored them in a quarantined setting. They will be followed up for 12 months after discharge.

No serious adverse events occurred, and the human challenge study model was shown to be safe and well tolerated in healthy young adults, the company said.

"People in this age group are believed to be major drivers of the pandemic and these studies, which are representative of mild infection, allow detailed investigation of the factors responsible for infection and pandemic spread," said Chris Chiu, chief investigator on the trial and professor of infectious diseases at Imperial.

The Imperial researchers said they now planned to start a similar study using the Delta variant, and will share their framework around the globe to allow similar research.

That could provide a crucial route to testing new vaccines, antivirals and diagnostics against COVID-19 more quickly, particularly if transmission rates fall in the real world.

Imperial said it could start tests like this using human challenge trials by the end of 2022.

In April, Oxford University launched another human challenge trial which sought to reinfect people to deepen understanding about immunity.

CLINICAL INSIGHTS

The results of the Imperial study, published on a pre-print server and yet to be peer reviewed, also provide some clinical insights that could inform public health policies.

Researchers found that symptoms start to develop on average about two days after contact with the virus, Imperial said, which is earlier than the widely held view that the virus has an incubation period of around five days.

The infection first appears in the throat; infectious virus peaks about five days into infection, which is also when the most significant symptoms are usually noticed, the researchers said. At that stage, the virus is significantly more abundant in the nose than the throat.

They also found that rapid lateral flow tests were a reliable indicator of whether infectious virus was present and therefore the person was likely to be able to transmit the virus. Most people had live virus in their nose for an average of 6.5 days, they said.

Eighteen volunteers became infected, 16 of whom went on to develop mild-to-moderate cold-like symptoms, including a stuffy or runny nose, sneezing, and a sore throat, Imperial said.

Some experienced headaches, muscle/joint aches, tiredness and fever. None developed serious symptoms.

Thirteen infected volunteers temporarily lost their sense of smell, but this returned within 90 days in all but three participants - the remainder continue to show improvement after three months.

There were no changes seen in their lungs, or any serious adverse events. Only one person had any lingering symptoms by six months - a slightly reduced sense of smell which was improving.

The trial used the lowest dose necessary to infect people, although the team said it was comparable to real-world infections.

The scientists will now study other elements from the trial, including investigating why the 16 of the 34 participants in the final analysis did not get infected despite exposure. Some had detectable virus in their nose but did not go on to test positive twice on PCR tests, the threshold the team used for confirmed infection.

(Reporting by Josephine Mason and Jennifer Rigby; Editing by Andrew Heavens and Alison Williams)

By Josephine Mason and Jennifer Rigby


ę Reuters 2022
All news about HVIVO PLC
03/16Inspirit Energy reports progress on Inspirit Charger
AN
03/16Inspirit Energy reports progress on Inspirit Charger
AN
02/06HVIVO signs GBP6.8 million deal to test RSV antiviral drug candidate
AN
02/06HVIVO Surges 10% on GBP7 Million RSV Drug Testing Contract With Asian Pacific Drugmaker
MT
02/06HVIVO plc Signs ú6.8 Million Contract with Leading Pharmaceutical Company Based in Asia..
CI
01/25Transcript : HVIVO plc - Special Call
CI
01/25FTSE 100 Closes Down 0.2%, Aviva Leads Gains
DJ
01/25EasyJet Must Do More Than Just Ride the Recovery
DJ
01/25HVIVO expecting record year; 2023 orderbook soars by 65% against 2022
AN
01/25EasyJet Shares Jump After Upbeat 1Q, Strong Outlook
DJ
More news
Analyst Recommendations on HVIVO PLC
More recommendations
Financials
Sales 2022 56,4 M 60,6 M 60,6 M
Net income 2022 5,37 M 5,78 M 5,78 M
Net cash 2022 31,0 M 33,3 M 33,3 M
P/E ratio 2022 21,7x
Yield 2022 -
Capitalization 114 M 123 M 123 M
EV / Sales 2022 1,47x
EV / Sales 2023 1,26x
Nbr of Employees 218
Free-Float 59,1%
Chart HVIVO PLC
Duration : Period :
hVIVO plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HVIVO PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,17 €
Average target price 0,32 €
Spread / Average Target 88,6%
EPS Revisions
Managers and Directors
Yamin Mohammed Khan Chief Executive Officer & Director
Stephen Pinkerton Chief Financial Officer & Executive Director
Cathal Martin Friel Non-Executive Chairman
Andrew Catchpole Chief Scientific Officer
Martin Ewart Johnson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HVIVO PLC54.00%127
MODERNA, INC.-16.81%57 628
LONZA GROUP AG18.91%43 764
SEAGEN INC.54.15%37 067
IQVIA HOLDINGS INC.-8.24%34 916
ALNYLAM PHARMACEUTICALS, INC.-19.84%23 646
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer